Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.
about
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and ValidationPlasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in MiceDisparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemiaPronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104BCL6 modulation of acute lymphoblastic leukemia response to chemotherapyThe future of patient-derived tumor xenografts in cancer treatment.Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia.Murine models of acute leukemia: important tools in current pediatric leukemia research.Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumorsStability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance.Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).Guidelines for the welfare and use of animals in cancer research.Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11)Initial testing of topotecan by the pediatric preclinical testing program.Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia.Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenograftsDexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine.Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.Molecular characterization of the pediatric preclinical testing panelStage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramInitial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemiaInitial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemiaIn vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice.Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing ProgramInitial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias.Initial testing (stage 1) of temozolomide by the pediatric preclinical testing programInitial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing programInitial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing programInitial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing programInitial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
P2860
Q26784048-16620171-960C-431D-B241-28BF6124C35CQ27304789-B2D5A50B-798A-4953-820D-3C6E4A24F4DAQ28483245-1C0C79D1-F6E0-4D4B-9311-BF2A95886A5DQ28741513-0894087A-1BB4-47D4-A499-4B0C00E3CA04Q28829626-EAC6D286-1C7F-4271-A0F2-D298BAC696C6Q33361578-DCFF6D79-C3D7-4B90-A7C2-DB68B796F9ADQ33433407-A83E14FC-F00E-4230-9543-33FB38247B7FQ33560521-BD9EBD63-0543-49DA-AA96-AF86AA56D362Q33606018-FD38A225-C484-4096-906A-693FFC3EA889Q33711691-1BDCB6CA-9CCE-4051-8D65-747DF1D344E7Q33755247-BF845B7A-A5EB-4852-B10C-EEEB9BA48963Q33867046-1AD6997E-D564-4A17-969E-936DCE9C012FQ33903753-34ABCA6E-7A65-4C16-9AD2-DC1485DBE7ADQ34005240-10029364-B710-410C-8339-DC10BE06DD02Q34073784-8BFE7888-8915-44A6-8180-9E6DF03001CFQ34076994-F0B9B1A4-E89B-49A1-9BDE-03AB6BC95BCDQ34135333-5F3C1A86-3285-4D5E-B797-E1CD935F5BA2Q34171019-A173748D-370D-49CF-B874-F7F6CFE011C2Q34221738-92BEFD26-516C-4742-B411-F6CA1CA967FFQ34249719-ED8E51E8-3A0A-43C0-B254-9A13E4D92C77Q34371357-002A98E5-4D12-4C88-9F96-D0BB5B3C5D3BQ34406965-08C412B4-8144-4979-8074-8996DA45BDDEQ34414736-CF03D2FD-E7A4-4DDA-AA09-A7C77144ADC1Q34415484-925F55A0-F9E6-48C7-A2AC-23193EC73BAEQ34448969-D47BAC4C-A620-43DF-B137-A38C36057ECEQ34475748-23A97966-4B0A-4F3C-BCB2-DAD0531A0EAEQ34475754-1B72B62D-2CE6-41A1-B2F0-412EBA734DC9Q34482552-D0FE9FB0-AEA8-4E21-BB70-1B1ED2A20FBDQ34541243-7178831C-E698-46FD-9F92-F307A256D4C1Q34543909-049C38FA-F616-4455-A88D-E67D0949DC71Q34561518-18A47506-61FB-46B4-8079-34161DA9727CQ34562163-7731C464-26AA-488E-A7E6-EBBCBBD58AC2Q34571940-DDB01ED8-553A-4886-822A-D22AD4827138Q34592429-4D95BBC8-7F42-447F-9CCB-C1823638B8F6Q34683782-B84E1AB8-56A6-4CB6-8455-0F1E70543217Q34683835-CE3371A9-FA70-44BF-85CC-41241BBA16F2Q35005290-96502C21-707D-466D-A578-AAB0A8B9C569Q35005309-00F1BE89-5A2D-405D-8FE5-D7A1D5D154DAQ35046326-7022ABE7-959F-4225-9247-3D96AA4F0FA2Q35079398-F5E09BC7-A4B3-4520-8F9F-8A2068696174
P2860
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Characterization of childhood ...... l evaluation of new therapies.
@en
type
label
Characterization of childhood ...... l evaluation of new therapies.
@en
prefLabel
Characterization of childhood ...... l evaluation of new therapies.
@en
P2093
P1433
P1476
Characterization of childhood ...... l evaluation of new therapies.
@en
P2093
Alison M Rice
Carole D Ramirez
Christopher G Milross
Karen L MacKenzie
Mayamin Tajbakhsh
Michelle Haber
Murray D Norris
Natalia L M Liem
Rachael A Papa
Richard B Lock
P304
P356
10.1182/BLOOD-2003-08-2911
P407
P577
2004-02-05T00:00:00Z